Background: Despite a low incidence of hypogammaglobulinemia (HG) in clinical trials using rituximab (RTX), HG occurs in follow-up of patients with autoimmune disease. Immunoglobulin replacement therapy (IRT) has been used to reduce infection rates but there is a paucity of data on its efficacy and impact on longer-term outcomes. We examined the characteristics of patients with RTX associated HG in autoimmune disease, and their long-term outcomes with and without IRT.